Charles Schwab Investment Management Inc. Trims Stake in OPKO Health, Inc. $OPK

Charles Schwab Investment Management Inc. trimmed its stake in OPKO Health, Inc. (NASDAQ:OPK) by 21.6% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,741,986 shares of the biotechnology company’s stock after selling 755,420 shares during the period. Charles Schwab Investment Management Inc. owned 0.35% of OPKO Health worth $4,552,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Oak Thistle LLC purchased a new stake in shares of OPKO Health in the 1st quarter worth $26,000. Cerity Partners LLC purchased a new stake in shares of OPKO Health in the 1st quarter worth $36,000. Pallas Capital Advisors LLC purchased a new stake in shares of OPKO Health in the 1st quarter worth $43,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 12,417 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its stake in shares of OPKO Health by 105.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 22,167 shares in the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

OPKO Health Stock Performance

Shares of OPKO Health stock opened at $1.42 on Friday. The firm has a market cap of $1.13 billion, a price-to-earnings ratio of -5.68 and a beta of 1.19. The business has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.45. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. OPKO Health, Inc. has a twelve month low of $1.11 and a twelve month high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.07). The firm had revenue of $156.80 million for the quarter, compared to analysts’ expectations of $165.74 million. OPKO Health had a negative net margin of 26.68% and a negative return on equity of 13.17%. The company’s revenue for the quarter was down 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.01) EPS. Equities research analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 675,000 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average price of $1.32 per share, with a total value of $891,000.00. Following the acquisition, the chief executive officer owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. The trade was a 0.32% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 49.69% of the stock is currently owned by insiders.

Analyst Ratings Changes

OPK has been the subject of several analyst reports. LADENBURG THALM/SH SH upgraded OPKO Health to a “strong-buy” rating in a research note on Tuesday, July 8th. Zacks Research upgraded OPKO Health from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 14th. Wall Street Zen lowered OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. Finally, Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research note on Thursday, May 1st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.